Anti-inflammatory drugs are medications that reduce inflammation in the body. These are commonly used to treat joint pain, arthritis, and other conditions associated with inflammation and pain. Some of the major classes of anti-inflammatory drugs include non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids/steroids, biologics, and interleukin blockers. NSAIDs including ibuprofen and naproxen are among the most commonly used anti-inflammatory medications due to their effectiveness and OTC availability. Growing geriatric population, rising prevalence of arthritis and other inflammatory diseases, increasing awareness about inflammatory conditions, and new product launches can drive the anti-inflammatory drugs market growth in the near future.

Market Dynamics:

Global anti-inflammatory drugs market growth is driven by factors such as growing geriatric population, rising prevalence of arthritis and other inflammatory diseases, increasing awareness about inflammatory conditions, new product approvals and launches. As per estimates, over 300 million people suffer from rheumatoid arthritis worldwide. The number of arthritis and inflammatory disease cases is projected to increase significantly due to aging population. This can boost demand for anti-inflammatory drugs for treatment of these diseases. However, factors such as adverse side effects of medications, patent expiries of blockbuster drugs, and development of alternatives like nutraceuticals can hamper the market growth. Emerging economies can offer lucrative opportunities for international players to expand their presence. Ongoing research on innovative formulation technologies and development of biologics with improved efficacy and safety profile can also offer new opportunities.

Key features of the study:

• This report provides in-depth analysis of the global anti-inflammatory drugs market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global anti-inflammatory drugs market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Pfizer, Johnson & Johnson, GlaxoSmithKline, Novartis, Abbott, Zydus Cadila, Sanofi, Merck, Roche, and Bayer
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global anti-inflammatory drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anti-inflammatory drugs market

Detailed Segmentation-

• By Drug Type
• • Nonsteroidal Anti-inflammatory Drugs (NSAlDs)
  • Immune Selective Anti-inflammatory Derivatives (ImSAlDs)
  • Anti-inflammatory Biologics
  • Corticosteroids
• By Application
• • Arthritis
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Multiple Sclerosis
  • Inflammatory Bowel Disease (IBD)
  • Gout
  • Others
• By Route of Administration
• • Oral
  • Topical
  • Injection
  • Inhalation
• By Distribution Channel
• • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:         
• • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
• • Pfizer, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Novartis AG
  • Eli Lilly and Company
  • Sanofi
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZenica PLC
  • Roche Holding AG
  • Bristol Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Gilead Sciences, Inc.
  • Horizon Therapeutics plc